| Jakafi (ruxolitinib) / Incyte |
| No Longer Available | N/A | | US | Ruxolitinib, Jakafi | Washington University School of Medicine, Incyte Corporation | Erythrocytosis, Familial, 2 | | | | |
ChiCTR2000029580: Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells: a prospective, single blind, randomized controlled clinical trial |
|
|
| Recruiting | N/A | 70 | China | Ruxolitinib combined with mesenchymal stem cell; Routine treatment | Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Wuhan Bureau of Science and Technology; Huazhong University of Science and Technology | novel coronavirus pneumonia (COVID-19) | | | | |
| No Longer Available | N/A | | NA | Ruxolitinib, Jakavi | Novartis Pharmaceuticals, Novartis is the Marketing Authorization Holder for Jakavi outside the US. | Severe/Very Severe COVID-19 Illness | | | | |
| Recruiting | N/A | 1300 | Europe | COVID-19 vaccines | Azienda Unità Sanitaria Locale Reggio Emilia, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Istituto Clinico Humanitas, IRCCS San Raffaele, Regina Elena Cancer Institute, Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" IRCCS, University of Roma La Sapienza, Fondazione IRCCS Policlinico San Matteo di Pavia, Istituti Fisioterapici Ospitalieri, Istituto Tumori Giovanni Paolo II, BARI, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, IRCCS Azienda Ospedaliero-Universitaria di Bologna | COVID-19, Solid Tumor, Hematologic Diseases, Neurologic Disorder, Rheumatic Diseases | 07/21 | 04/22 | | |
NCT04355793: Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection |
|
|
| No Longer Available | N/A | | NA | Ruxolitinib, INCB018424 | Incyte Corporation | COVID-19 | | | | |
ChiCTR2100042673: Population Pharmacokinetic Modelling to Assess the Drug- Drug Interactions between Voriconazole and Ruxolitinib |
|
|
| Recruiting | N/A | 12 | | Take 5mg ruxolitinib orally | The First Medical Center of Chinese PLA General Hospital; Chinese PLA General Hospital, the National Natural Science Foundation of China (No. 82070178, and 81170203) | Graft versus host disease | | | | |
NCT04351503: A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19 |
|
|
| Completed | N/A | 126586 | Europe | Study A, Study B, Study C, Study D | University Hospital, Basel, Switzerland, sciCORE University of Basel, Leonhard Med IT ETH Zurich, Swiss Institute of Bioinformatics | SARS Coronavirus (SARS-CoV-2) Infection | 07/22 | 07/22 | | |
RUX-MF, NCT06516406: Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera |
|
|
| Recruiting | N/A | 1055 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Myelofibrosis, Primary Myelofibrosis, Secondary Myelofibrosis | 05/32 | 05/32 | | |
| Completed | N/A | 319 | Europe, RoW | Ruxolitinib, Extracorporeal photopheresis, Ibrutinib | European Society for Blood and Marrow Transplantation, Mallinckrodt | Steroid Refractory GVHD | 06/22 | 06/22 | | |
ChiCTR1900025078: Clinical study for the safety and efficacy of ruxolitinib combined with desitabine in the treatment of MPN patients in accelerated and blast phase |
|
|
| Recruiting | N/A | 108 | | desitabine ;ruxolitinib+desitabine ;desitabine+half does of CAG ;ruxolitinib+desitabine+half does of CAG | The Second Hospital of Tianjin Medical University; The Second Hospital of Tianjin Medical University, Tianjin Medical University Second Hospital | myeloproliterative neoplasms | | | | |
ChiCTR1900027971: Clinical study for ruxolitinib in the prevention of acute graft-versus-host disease |
|
|
| Recruiting | N/A | 160 | | Ruxolitinib+CSA+MTX+MMF ;CSA+MTX+MMF | The Second Hospital of Hebei Medical University; the Second Hospital of Hebei Medical University, Self-financing | Malignant hematopathy | | | | |
NCT04526223: Outcomes of MF Patients Exposure to Ruxolitinib During Transplantation |
|
|
| Recruiting | N/A | 30 | RoW | comprehensive treatment regimen | xuna | Time of Hematopoietic Reconstruction | 12/22 | 12/22 | | |
ChiCTR2100053519: A pilot study of ruxolitinib in the prevention of acute graft-versus-host disease |
|
|
| Completed | N/A | 40 | | Ruxolitinib + CSA + MTX + MMF, from +1 day ;Ruxolitinib+CSA+MTX+MMF, from neutrophil engraftment confirmation day | The Second Hospital of Hebei Medical University; The Second Hospital of Hebei Medical University, self-financed | acute graft-versus-host disease | | | | |
| Available | N/A | | NA | Ruxolitinib, Jakavi | Novartis Pharmaceuticals | Polycythemia Vera | | | | |
PAVE, NCT05853445: A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera |
|
|
| Completed | N/A | 467 | Europe | Jakavi, Ruxolitinib | Novartis Pharmaceuticals | Polycythemia Vera | 05/23 | 05/23 | | |
ChiCTR2200059961: Drug-Drug Interactions between Posaconazole and ruxolitinib in patients with hematological diseases |
|
|
| Not yet recruiting | N/A | 12 | | 5mg ruxolitinib orally | Chinese PLA General Hospital; Chinese PLA General Hospital, Sub-topics of Major Projects of Ministry of Science and Technology (2018ZX09201018-022) | Hematological malignancies | | | | |
| Completed | N/A | 189 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Adherence, Patient, Adherence, Treatment | 06/23 | 06/23 | | |
| Available | N/A | | NA | Ruxolitinib, INC424 | Novartis Pharmaceuticals | Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF), Thrombocythemia Myelofibrosis (PET-MF), Severe/Very Severe COVID-19 Illness, Polycythemia Vera (PV), Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD), Steroid Refractory Chronic Graft Versus Host Disease (SR cGVHD) | | | | |
NCT06151119: 68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis. |
|
|
| Recruiting | N/A | 90 | RoW | 68Ga FAPI PET/CT | The First Affiliated Hospital of Xiamen University | Primary Myelofibrosis | 10/24 | 06/25 | | |
ChiCTR2100051874: Efficacy and safety of ruxolitinib in preventing aGVHD after haplotype bone marrow transplantation in severe aplastic anemia |
|
|
| Recruiting | N/A | 20 | | ruxolitinib | The Second Affiliated Hospital of Dalian Medical University; The Second Affiliated Hospital of Dalian Medical University, Liaoning Provincial Key Laboratory of Hematopoietic Stem Cell Transplantation Clinical Translational Medicine Fund | Severe aplastic anemia | | | | |
| Not yet recruiting | N/A | 153 | NA | | Gruppo Italiano Malattie EMatologiche dell'Adulto | Polycythemia Vera | 07/25 | 07/25 | | |
| Recruiting | N/A | 150 | RoW | Tofacitinib, Baricitinib, Ruxolitinib, Upadacitinib, Abrocitinib, Ritlecitinib | Second Affiliated Hospital, School of Medicine, Zhejiang University | Alopecia Areata, Janus Kinase Inhibitors | 12/26 | 12/26 | | |
| Not yet recruiting | N/A | 80 | | Oral ruxolitinib 10 mg q12h (5 mg q12h if creatinine clearance was less than 30 ml/min) for 10 days or until discharge from the hospital with improvement (up to a maximum of 10 days),along with the standard of care.; Standard of care | Juxian People's Hospital; Qilu Hospital of Shandong University, Clinical Research Project of Shandong University, 2021 (2021SDUCRCC004). | severe fever with thrombocytopenia syndrome | | | | |
| Not yet recruiting | N/A | 51 | NA | Ruxolitinib | Assiut University | Myelofibrosis | 03/25 | 06/25 | | |
NCT05899725: The Efficacy and Safety of Corticosteroids in Combination With Ruxolitinib in the Management of Checkpoint Inhibitor Pneumonia |
|
|
| Recruiting | N/A | 60 | RoW | Corticosteroids, Corticosteroids and Ruxolitinib | Peking Union Medical College Hospital | Severe Checkpoint Inhibitor Pneumonitis | 03/25 | 06/25 | | |
ChiCTR2400083226: A dose-exploration clinical study evaluating the combination of Ruxolitinib and luspatercept in the treatment of myelofibrotic anemia in subjects |
|
|
| Recruiting | N/A | 18 | | Ruxolitinib maintains the original therapeutic dose,Luspatercept with a starting dose of 1.0mg/kg. The second titration reaches 1.33mg/kg, and the third titration reaches 1.75mg/kg; Ruxolitinib maintains the original therapeutic dose,Luspatercept with a starting dose of 1.33mg/kg. The second titration reaches 1.75mg/kg, and the third titration reaches 2.0mg/kg; Ruxolitinib maintains the original therapeutic dose,Luspatercept with a starting dose of 1.5mg/kg. The second titration reaches 2.0mg/kg, and the third titration reaches 2.5mg/kg | West China Hospital of Sichuan University; West China Hospital of Sichuan University, Beijing Life Oasis Public Welfare Service Center | myelofibrosis | | | | |
| Recruiting | N/A | 90 | Canada | Hematopoietic stem cell transplant, Ruxolitinib, JAKAVI, Hydroxyurea | University Health Network, Toronto | Myelofibrosis, High-Risk Cancer, Bone Marrow Cancer | 08/25 | 02/26 | | |
| Recruiting | N/A | 127 | RoW | ruxolitinib, Jakavi | Novartis Pharmaceuticals | Graft-versus-Host Disease | 05/26 | 05/26 | | |
Prospero, NCT05548062: Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera |
|
|
| Active, not recruiting | N/A | 241 | Europe | Hydroxyurea, Ruxolitinib | Novartis Pharmaceuticals | Polycythemia Vera | 08/27 | 08/27 | | |
